Increasing use of expensive specialty drugs will drive Medicare Part D benefits costs up by 9.5% each year over the next 10 years, a Medicare Trustees report forecasts. The report is evidence that projected spending on specialty drugs can't be sustained over the long run and that more work is needed to bring biosimilars to market, according to this article.

Full Story:
RxObserver blog

Related Summaries